Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBF 77 EV-to-EBIT is 24.61 as of Jul. 24, 2026, which is 17% below its 10-year median of 29.57. GuruFocus rates CLPBF with a GF Score™ of 77/100 and a GF Value™ of $126.03 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Coloplast AS ranks worse than 68.82% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Coloplast AS's Enterprise Value for the quarter that ended in Mar. 2026 was $18,565 Mil.
Coloplast AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $701 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS EV-to-EBIT Related Terms
Coloplast AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Coloplast AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Coloplast AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Coloplast AS's EV-to-EBIT falls into.
Coloplast AS's current Enterprise Value is $17,253 Mil.
Coloplast AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $701 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a EV-to-EBIT of 24.61 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Coloplast AS and its competitors. This is 17% below median its historical median of 29.57. Over the past decade, Coloplast AS's EV-to-EBIT has ranged from 16.35 to 68.86. According to the industry distribution chart, Coloplast AS ranks #320 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 68.8%.
Is Coloplast AS's EV-to-EBIT too high?
Coloplast AS's current EV-to-EBIT of 24.61 is 17% below median its 10-year median of 29.57. Over the past 10 years, this metric has ranged from a low of 16.35 to a high of 68.86. The Medical Devices & Instruments industry median EV-to-EBIT is 18.19. Coloplast AS's value of 24.61 is 35.3% above this industry median. Based on the distribution chart, Coloplast AS ranks #320 out of 465 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #320 out of 465 companies for EV-to-EBIT. This places Coloplast AS in the lower half of its industry. The industry median EV-to-EBIT is 18.19. Coloplast AS's value of 24.61 is 35.3% above this benchmark. Historically, Coloplast AS's own EV-to-EBIT has ranged from 16.35 to 68.86 over the past decade. While the company's 10-year median is 29.57 vs. the industry median of 18.19, Coloplast AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.19, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current EV-to-EBIT of 24.61 is 35.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current EV-to-EBIT is 24.61, which is 17% below median its own 10-year median of 29.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.03, compared to a current price of $64.00 — trading 49.2% below its estimated fair value. The current EV-to-EBIT is 24.61, which is 17% below median its 10-year median of 29.57 and 35.3% above the Medical Devices & Instruments industry median of 18.19. Coloplast AS's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current EV-to-EBIT is 24.61 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $64.00 is trading 49.2% below its estimated GF Value™ of $126.03.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
EV-to-EBIT: 24.61 (17% below median its 10-year median of 29.57)
GF Value™: $126.03 vs. price of $64.00 (49.2% below fair value)
Industry Position: 35.3% above the Medical Devices & Instruments median (#320 of 465)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
